_800x533_L_1412520412.jpg)
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lakefront Biotherapeutics NV ADR (LKFT)
The Lakefront Bio ADR share price today is 27.00, view NASDAQ LKFT stock exchange data. Track the latest Lakefront Bio ADR share price with real-time updates on LKFT stock performance including market cap, day range, 52-week range and dividend yield. Access LKFT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.64
27.09
52 wk Range
25.68
37.78
Earnings results expected in 3 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
26.6427.09
52 wk Range
25.6837.78
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LKFT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
25.51
Downside
-5.52%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
2_800x533_L_1412520354.jpg)
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
0 Buy
4 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 25.51
(-5.52% Downside)
Lakefront Biotherapeutics NV ADR Earnings Call Summary for Q1/2026
- Galapagos Q1 2026 EPS of $0.25 beat estimates by 126%, but revenue of $7.6M missed forecasts by 77% due to absent legacy OLCA revenue.
- Operating loss improved 60% YoY to $63.7M; net profit swung to $14.5M from $153.4M loss, driven by cost management and FX gains.
- Company holds $2.98B cash with 20.15 current ratio; Ouro Medicines transaction expected to close Q2 2026 with significant cash outlay.
- Stock declined 0.42% premarket; EPS projections remain negative through FY2027 despite strategic transformation efforts underway.
- CEO emphasized cost reduction success and Gamgertamig pipeline potential; management confident in competitive positioning amid revenue volatility.
Last Updated: 07-05-2026, 06:16 pm
Read Full TranscriptEarnings
Latest Release
06-05-2026
EPS / Forecast
0.25 / -0.95
Revenue / Forecast
7.63M / 33.59M
Compare LKFT to Peers and Sector
Metrics to compare | LKFT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLKFTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.2x | 19.6x | −0.4x | |
PEG Ratio | 0.01 | 0.19 | 0.00 | |
Price/Book | 0.5x | 3.8x | 2.6x | |
Price / LTM Sales | 1.5x | 5.0x | 3.0x | |
Upside (Analyst Target) | 5.1% | 12.4% | 50.7% | |
Fair Value Upside | Unlock | 5.1% | 7.2% | Unlock |
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Lakefront Bio ADR (LKFT) Share Price Today?
The Lakefront Bio ADR share price today is 27.00.
What is the current Lakefront Bio ADR (LKFT) share price and day range?
As of 07-08-2026, the Lakefront Bio ADR share price is 27.00, with a previous close of 26.13. The share price has ranged from 26.64 to 27.09 today, while the 52-week range spans from 25.68 to 37.78.
What Is the Lakefront Bio ADR Market Cap?
As of today, Lakefront Bio ADR market cap is 1.78B.
What Is the Lakefront Bio ADR (LKFT) Share Price Target?
The average 12-month share price target for Lakefront Bio ADR is 25.51, with a high estimate of 30.23850674 and a low estimate of 18.83857587. 0 analysts recommend buying, while 1 suggest selling, with an overall rating of Neutral and -5.52% Downside potential.
What Is Lakefront Bio ADR's Earnings Per Share (TTM)?
The Lakefront Bio ADR EPS (TTM) is 7.40.
When Is the Next Lakefront Bio ADR Earnings Date?
Lakefront Bio ADR will release its next earnings report on 10-08-2026.
From a Technical Analysis Perspective, Is LKFT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Lakefront Bio ADR Trade On?
Lakefront Bio ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lakefront Bio ADR?
The stock symbol for Lakefront Bio ADR is "LKFT."
How Many Times Has Lakefront Bio ADR Stock Split?
Lakefront Bio ADR has split 0 times.
How Many Employees Does Lakefront Bio ADR Have?
Lakefront Bio ADR has 452 employees.
What Is the LKFT Premarket Price?
LKFT's last pre-market stock price is 26.80. The pre-market share volume is 950.00, and the stock has changed by 0.67, or 2.56%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.